An "enhanced information service" for former residents of mother and baby homes regarding trials that took place between 1934 and 1973 has been established by the pharmaceutical company GlaxoSmithKline (GSK).

The Mother and Baby Homes Report noted vaccine trials were carried out in institutions examined by the commission.

GSK is made up of two companies which carried out seven different trials in mother and baby institutions.

They took place at Bessborough, Pelletstown, Dunboyne and Castlepollard – with trials for vaccines including measles and polio to diphtheria.

The commission found there wasn't compliance with the relevant regulatory and ethical standards at the time. Consent was not obtained from either the mothers or the children, or their guardians.

Following the publication of the report, the company said it acknowledged "the publication of the final report of the Mother and Baby Homes Commission of Investigation", and thanked the members of the commission for "reviewing the conduct of clinical studies" which took place in institutions in Ireland between 1934 and 1973.

GSK said it had fully cooperated with the commission - providing documents from its historic archives.

Today it has announced an information service for survivors consisting of "a more simplified information request service".

It also includes the publication of trial summary documents for nine separate trials - vaccine trials A to G, as they are referred to in the commission's report, as well as two infant milk formula trials.

In a statement issued today, GSK says it recognises that many survivors are "understandably seeking to access their personal information".

The company says it has spent time reflecting on its response to the Commission's report and has endeavoured to find a meaningful way to assist survivors and their families.

It says it believes the measures undertaken to simplify the information request service and publish trial summary documents represents "the most valuable way to support those seeking further transparency in relation to the trials".

Demand for information - known as a 'subject access request’ - has increased since the publication of the Commission of Investigation’s report according to the company.

It says it wants to ensure that survivors who believe they may have been a participant in a trial are aware they have a statutory right to submit an information request to the company in relation to their personal information.

It also notes, however, that the records are "not complete for every trial".

GSK says while some of the individual clinical trial records contain important identifying information such as names and dates of birth, this information is not available for all trials.

"This means it is not possible to verify the identity of every participant and part of the reason why GSK has also published trial summary documents with information about the development and, where applicable, the licensing history of the trial products".

The trial summary documents are also available on the GSK website and contains information relating to vaccine trials A to G and two infant milk formula trials.

The documentation has been collated from GSK's archives in London as well as other published sources to evaluate, as far as possible, the history of the vaccine or milk products after their trials were conducted by researchers in mother and baby institutions.

GSK concludes its statement saying it "would like to re-emphasise its sympathies to the women, children and families affected by the issues raised in the commission’s report and sincerely hopes the work undertaken to enhance its information service and publish trial summaries will better support those searching for more information about their personal experience or that of a family member".

Those seeking information to the trials can find it on GSK website.